The Series A round will enable BLUU Seafood to advance its cell-grown fish meat technology towards pilot production and marketing in Singapore.

BLUU Seafood, a leading European food biotech, has closed its Series A funding round, raising EUR 16 million (US$ 17.5 million). The German start-up plans to use the capital to advance its technology and launch its first products. Cultivated fish, grown directly from fish cells, provides real animal protein without animal slaughter.

Sparkfood and LBBW VC led the funding round, with participation from SeaX Ventures, Manta Ray Ventures, Norrsken VC, Delivery Hero, Innovationsstarter Fonds Hamburg GmbH, and Dr. Oetker. BLUU Seafood has raised over EUR 23 million since its 2020 founding. (CISION PR Newswire)

The funds will be utilized for regulatory approval, research expansion, and pilot production. The company will focus on hybrid products, blending cultivated fish cells with plant-based proteins, such as fish balls and fish fingers. BLUU Seafood aims to enter the Singapore market by 2024, following the approval of cultivated chicken sales in 2020.

The company said the raise showcased the immense potential of cultivated fish as a platform technology for sustainable animal protein. In the US, cultivated meat and fish are set to launch after USDA and FDA approvals for start-ups like GOOD Meat and UPSIDE Foods.

BLUU Seafood has initiated the FDA approval process and plans to expand in Europe. The company is preparing to open a pilot production plant, scaling up from lab-scale to larger fermenters up to 500 liters.

Related Story:  Higher Steaks, Now Rebranding As Uncommon, Raises $30M For Its Cultivated Meats